WASHINGTON, D.C. and NORWELL, Mass. — Three of the nation’s leading federal health officials are scheduled to take center stage alongside more than 900 rare disease leaders representing patient advocacy, industry, policy, science, and medicine. The high-profile gathering will take place at the 2026 NORD® Rare Diseases and Orphan Products Breakthrough Summit®, scheduled for October 25 through October 27 in Washington, D.C.
The prominent officials participating in the event include Kyle Diamantas, J.D., Acting Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA); Jay Bhattacharya, M.D., Ph.D., Director of the National Institutes of Health (NIH); and Stephanie E. Haridopolos, M.D., DABFM, Director of National Health Communications for the Office of the Surgeon General and Principal Deputy Assistant Secretary for Health Policy.
As these leaders prepare to address the 16th annual NORD Breakthrough Summit, they join a diverse community of stakeholders dedicated to tackling the most pressing challenges and exploring new opportunities. Together, they aim to scale healthcare solutions for the more than 30 million children and adults across the United States who are currently living with rare diseases.
Pam Gavin, Chief Executive Officer of NORD, emphasized the critical timing of the upcoming conference and the significance of high-level government participation.
"Rare disease is at a pivotal moment, and it is important for our community to hear directly from the federal leaders helping shape what comes next," said Pam Gavin, Chief Executive Officer of NORD. "Their presence at the NORD Breakthrough Summit reflects our longstanding partnership and continued collaboration with the FDA, NIH and Office of the Surgeon General, as well as their commitment to the rare disease community. The work they lead across research, regulation and public health is critical to building on today’s scientific breakthroughs and translating that progress into meaningful advances for people living with rare diseases."
The annual summit serves as a vital meeting ground for cross-sector collaboration, drawing individuals who are deeply invested in finding treatments, accelerating diagnoses, and improving the overall quality of life for rare disease patients. With advanced scientific methodologies continuing to reshape the medical landscape, the involvement of federal agencies remains a cornerstone in navigating regulatory pathways and fostering innovative research.
FDA Acting Commissioner Kyle Diamantas
As Acting Commissioner of Food and Drugs, Kyle Diamantas leads the federal agency responsible for safeguarding public health by regulating human and veterinary drugs, biological products, medical devices, and diagnostics. These regulatory functions are vital to advancing care and expanding treatment options for individuals living with rare diseases, where therapeutic options have historically been scarce.
In one of his first notable actions in the role, Acting Commissioner Diamantas organized a dedicated roundtable with rare disease advocates, including representatives from NORD. The session was designed to listen directly to community concerns and understand how the FDA can better meet the unique regulatory challenges faced by rare disease populations.
His upcoming participation at the Breakthrough Summit will provide attendees with a direct channel to hear from FDA leadership regarding the regulatory priorities, modern evaluation pathways, and collaborative frameworks that are shaping the future of rare disease innovation.
NIH Director Jay Bhattacharya
As Director of the National Institutes of Health, Dr. Jay Bhattacharya oversees the nation’s premier biomedical research enterprise. The NIH plays a foundational role in funding and conducting the scientific discoveries that ultimately underpin new diagnostic tools, targeted treatments, and potential cures for complex conditions.
The scope of contemporary biomedical research spans numerous cutting-edge domains. From the strategic application of artificial intelligence and machine learning to electronic health record data, to public-private partnerships establishing standardized platforms for gene-targeted therapies, the NIH stands at the forefront of modern science. These initiatives are central to accelerating the development and delivery of advanced gene therapies for rare conditions.
Dr. Bhattacharya’s perspective is considered critical for understanding how the various specialized institutes and centers within the NIH coordinate their efforts. By working collaboratively, these entities strive to support both adults and children who are affected by one or more rare diseases, bridging the gap between basic laboratory research and clinical application.

Director of National Health Communications for the Office of the Surgeon General and Principal Deputy Assistant Secretary for Health Policy, Stephanie E. Haridopolos
Dr. Stephanie E. Haridopolos brings a longstanding, personal commitment to rare disease advocacy to her prominent roles within the Office of the Surgeon General and the Office of the Assistant Secretary for Health. During the upcoming Summit, Dr. Haridopolos is scheduled to speak extensively on her ongoing work surrounding Newborn Screening.
In recognition of her significant contributions to public health policy, Dr. Haridopolos will be presented with NORD’s 2026 Rare Impact Award® in the category of Policy Changemaker. Her policy leadership was notably demonstrated in 2025, when two rare conditions—Duchenne muscular dystrophy and metachromatic leukodystrophy—were successfully added to the Recommended Uniform Screening Panel (RUSP).
Furthermore, Dr. Haridopolos has served as a critical contributor to the Newborn Screening Working Group. This specialized group is tasked with systematizing operational procedures for the RUSP, thereby expanding opportunities for earlier diagnosis and timely clinical intervention for newborns affected by rare disorders.
Broad Federal Representation and Regulatory Engagement
In addition to keynote remarks from individual leaders, the Summit will feature a comprehensive federal regulatory panel. This panel will include senior representatives from key FDA divisions, including the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the specialized Rare Disease Innovation Hub.
This multi-center assembly will bring together diverse regulatory perspectives spanning traditional small molecule drugs, complex biologics, cell and gene therapies, as well as cutting-edge medical devices and diagnostic tools. Such cross-disciplinary dialogue is essential for addressing the intricate hurdles inherent in translating laboratory innovations into commercially viable, accessible medical products.
A Critical Moment for the Rare Disease Community
For the more than 30 million Americans currently facing a rare disease diagnosis, the present era represents a deeply significant juncture. Rapid advancements in biomedical science are continuously unlocking new possibilities for achieving earlier diagnoses and developing targeted treatments. However, these emerging technologies and novel therapeutic development paradigms also place unprecedented demands on the nation’s research, regulatory, and healthcare systems to keep pace.
The robust participation of federal health leaders underscores the absolute necessity of cross-sector collaboration. By working in tandem across government agencies, academic research institutions, clinical medicine, industry, and the patient community, stakeholders can more effectively translate scientific progress into tangible outcomes. The ultimate goal remains achieving faster diagnoses, expanding the availability of effective treatments, and securing better health outcomes for the roughly 1 in 10 Americans impacted by a rare disease.
Now celebrating its 16th year, the NORD Breakthrough Summit has firmly established itself as the nation’s premier professional gathering dedicated exclusively to rare diseases and orphan products. The 2026 event will convene a diverse array of more than 900 stakeholders whose collective expertise is required to drive sustained progress across research, therapeutic development, clinical care, policy formulation, and patient access.
Individuals interested in reviewing the complete agenda, exploring additional event details, or registering to attend can visit the official event website at NORDSummit.org.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) is an independent, nonprofit, nonpartisan organization dedicated to improving the health and lives of the more than 30 million Americans living with rare diseases. Working in close partnership with over 350 disease-specific member patient organizations and a comprehensive Rare Disease Centers of Excellence network spanning more than 170 medical institutions, research facilities, and children’s hospitals, NORD actively advances care, scientific research, education, and public policy advocacy on behalf of the entire rare disease community. Additional information can be found online at rarediseases.org.
Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders (NORD)
Email: [email protected]
Phone: 719-330-4053
